Low-dose interleukin-11 in patients with bone marrow failure: Update of the M. D. Anderson Cancer Center experience

Annals of Oncology

Volumn 16, Issue 1, 2005, Pages 139-145

  Tsimberidou, A M ^a   Giles, F J ^a   Khouri, I ^a   Bueso Ramos, C ^a   Pilat, S ^a   Thomas, D A ^a   Cortes, J ^a   Kurzrock, R ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Cytokine; Growth factor; Proliferation; Thrombocytopenia

Indexed keywords

AMIFOSTINE; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; ERYTHROPOIETIN; FUROSEMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; HEMOGLOBIN; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT INTERLEUKIN 11; STEM CELL FACTOR; STEROID; THYMOCYTE ANTIBODY; TOPOTECAN;

ADOLESCENT; ADULT; AGED; APLASTIC ANEMIA; ARTHRALGIA; ARTICLE; ASCITES; BONE MARROW DEPRESSION; BONE PAIN; BREAST TENDERNESS; BURNING SENSATION; CANCER CENTER; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CONJUNCTIVA DISEASE; CONTROLLED STUDY; CONVALESCENCE; CYTOGENETICS; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FLU LIKE SYNDROME; GASTROENTERITIS; GRAFT FAILURE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN CELL; HYPOTHYROIDISM; INFECTIOUS PNEUMONIA; INJECTION SITE REACTION; KIDNEY FAILURE; LEG EDEMA; LEUKOCYTE COUNT; LOW DRUG DOSE; MAINTENANCE THERAPY; MALE; MYALGIA; MYCOSIS; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NEUTROPHIL; PERICARDIAL DISEASE; PERIPHERAL EDEMA; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL ANALYSIS; STEM CELL TRANSPLANTATION; SUPRAVENTRICULAR TACHYCARDIA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA, APLASTIC; BONE MARROW DISEASES; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT REJECTION; HUMANS; INTERLEUKIN-11; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 12344288374     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi007     Document Type: Article

References (42)

1. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med 1999; 340: 1649-1660.
2. Benson K, Fields K, Hiemenz J et al. The platelet-refractory bone marrow transplant patient: prophylaxis and treatment of bleeding. Semin Oncol 1993; 20: 102-109.
3. Du X, Williams DA. Interleukin-11: review of molecular, cell biology, and clinical use. Blood 1997; 89: 3897-3908.
4. Isaacs C, Robert NJ, Bailey FA et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 1997; 15: 3368-3377.
5. Ferrari S, Danova M, Porta C et al. Recombinant human interleukin-11 reduces thrombocytopenia in breast cancer patients receiving tandem autologous circulating progenitor cell transportation. Ann Hematol 2002; 81: 354-356.
6. Kurzrock R, Cortes J, Thomas DA et al. Pilot study of low-dose interleukin-11 in patients with bone marrow failure. J Clin Oncol 2001; 19: 4165-4172.
7. Cheson BD, Bennett JM, Kantarjian H et al. World Health Organization international working group. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671-3674.
8. Wu H, Talpaz M, Champlin RE et al. Sequential IL-3 and GM-CSF therapy in bone barrow failure with long-term follow-up of responses. Cancer 2003; 98: 2410-2419.
9. Kurzrock R, Gratwohl A, Paquette R et al. Trilineage responses seen with stem cell factor and filgrastim treatment in aplastic anemia patients. Br J Haematol 1998; 102: 1 (Abstr).
10. Bussel JB, Mukherjee R, Stone AJ. A pilot study of rhuIL-11 treatment of refractory ITP. Am J Hematol 2001; 66: 172-177.
11. Greenberg PL, Negrin R, Nagler A. Effects of CSFs in preleukemia. Bone Marrow Transplant 1990; 6 (Suppl 1): 121-126.
12. Willemze R, van der Lely N, Zwierzina H et al. A randomized phase-I/II multicenter study of recombinant human granulocyte - macrophage colony-stimulating factor therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. EORTC Leukemia Cooperative Group. Ann Hematol 1992; 64: 173-180.
13. Schuster MW, Larson RA, Thompson JA et al. Granulocyte macrophage colony stimulating factor for myelodysplastic syndrome: results of a multicenter randomized controlled trial. Blood 1990; 76: 318a (Abstr).
14. Kurzrock R, Talpaz M, Gomez JA et al. Differential dose-related haematological effects of GM-CSF in pancytopenia: evidence supporting the advantage of low- over high-dose administration in selected patients. Br J Haematol 1991; 78: 352-358.
15. Negrin RS, Haeuber DH, Nagler A et al. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 1990; 76: 36-43.
16. Greenberg P, Taylor K, Larson R et al. Phase III randomized multicenter trial of G-CSF vs. observation for myelodysplastic syndrome. Blood 1993; 82: 196a (Abstr).
17. Lowenberg B, van Putten W, Theobald M et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003; 349: 743-752.
18. Kurzrock R, Talpaz M, Estey E et al. Erythropoietin treatment in patients with myelodysplastic syndrome and anemia. Leukemia 1991; 5: 985-990.
19. Bessho M, Jinnai I, Matsuda A et al. Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia. Int J Cell Cloning 1990; 8: 445-458.
20. Stein RS, Abets RI, Krantz SB. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood 1991; 78: 1658-1663.
21. Verhoef GE, Zachee P, Ferrant A et al. Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment. Ann Hematol 1992; 64: 16-21.
22. Cazzola M, Ponchio L, Beguin Y et al. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. Blood 1992; 79: 29-37.
23. Liu Yin JA, Adams JA, Brereton ML et al. Megakaryopoiesis in vitro in myelodysplastic syndromes and acute myeloid leukaemia: effect of pegylated recombinant human megakaryocyte growth and development factor in combination with other growth factors. Br J Haematol 2000; 108: 743-746.
24. Nash RA, Kurzrock R, DiPersio J et al. A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2000; 6: 25-34.
25. Kurzrock R, Talpaz M, Estrov Z et al. Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol 1991; 9: 1241-1250.
26. Talpaz M, Patterson M, Kurzrock R. Sequential administration of IL-3 and GM-CSF in bone marrow failure patients: a phase I study. Blood 1994; 84: 28a (Abstr).
27. Gordon MS. Advances in supportive care of myelodysplastic syndromes. Semin Hematol 1999; 36: 21-24.
28. List AF, Brasfield F, Heaton R et al. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood 1997; 90: 3364-3369.
29. Grossi A, Fabbri A, Santini V et al. Amifostine in the treatment of low-risk myelodysplastic syndromes. Haematologica 2000; 85: 367-371.
30. Cantoni A, Silvestri F, Buanamici S et al. Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol 2004; 41: 13-20.
31. Silverman LR, Demakos EP, Peterson BL et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002; 20: 2429-2440.
32. Mufti G, List AF, Gore SD, Ho A. Myelodysplastic syndrome. Hematology (AM Soc Hematol Educ Program) 2003; 176-199.
33. Bessho M, Jinnai I, Hirashima K et al. Trilineage recovery by combination therapy with recombinant human granulocyte colony-stimulating factor and erythropoietin in patients with aplastic anemia and refractory anemia. Stem Cells 1994; 12: 604-615.
34. Imai Y, Fukuoka T, Nakatani A et al. Sustained trilineage recovery and disappearance of abnormal chromosome clone in a patient with myelodysplastic syndrome following combination therapy with cytokines (granulocyte colony-stimulating factor and erythropoietin) and high-dose methylprednisolone. Br J Haematol 1996; 93: 146-150.
35. Kurzrock R, Talpaz M, Gutterman JU. Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anemia. Am J Med 1992; 93: 41-48.
36. Momose K, Taguchi K, Saitoh M et al. Effects of interleukin-11 on the hematopoietic action of granulocyte colony-stimulating factor. Arzneimittelforschung 2002; 52: 857-861.
37. Estey EH, Thall PF, Giles FJ et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood 2002; 99: 4343-4349.
38. Tsimberidou AM, Estey E, Cortes J et al. Randomized comparison of idarubicin and Ara-C±interleukin-11 in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndrome. Proc Am Soc Clin Oncol 2003; 22: 585 (Abstr).
39. Ellis M, Zwaan F, Hedstrom U et al. Recombinant human interleukin 11 and bacterial infection in patients with haematological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised trial. Lancet 2003; 361: 275-280.
40. Bessho M, Hirashima K, Asano S et al. Treatment of the anemia of aplastic anemia patients with recombinant human erythropoietin in combination with granulocyte colony-stimulating factor: a multicenter randomized controlled study. Multicenter Study Group. Eur J Haematol 1997; 58: 265-272.
41. Lee JH, Shin YR, Lee JS et al. Spontaneous remission of aplastic anemia: a retrospective analysis. Haematologica 2001; 86: 928-933.
42. Saitoh T, Saiki M, Kumagai T et al. Spontaneous clinical and cytogenetic remission of aplastic anemia in a patient with del(13q). Cancer Genet Cytogenet 2002; 136: 126-128.